Prof. Eitan Kerem, MD, a world known leader in Cystic Fibrosis research, is a principal investigator of numerous national and international multicenter clinical trials. He is the author of seminal publications in the field, including phenotype-genotype relationships, disease prognostic factors, the molecular mechanisms for disease variability, and the development of novel mutation-specific pharmacological therapies to correct the basic defects in cystic fibrosis.
His many interests extend beyond cystic fibrosis, and he has been central to studies examining environmental interactions with genetic diseases and its influence on the disease severity, genetic markers of asthma and allergy in closed populations, and variability of disease in closed populations exposed to different environments. Increasingly, his efforts have turned to understanding the genetics of primary ciliary dyskinesia in Jewish and Palestinian children. In addition he published leading papers on management of community acquired pneumonia in children and was the first to characterize nectrotizing pneumonia and risk factors for complicated pneumonia in children.
The promotion of the medical, ethical and rights aspects of children with chronic diseases is at the forefront of his interest. He published many papers in this field and is known for his advocacy for children in need.
He also has a record of building bridges between Israelis and Palestinians furthering peace through medicine wherever possible.
Professor Kerem received a number of prestigious awards the last being the European CF Society Award in 2014.
He has authored over 170 papers covering all aspects of Pulmonology.